The gene for tyrosine-kinase receptor Ron (MST1R) resides in the chromosome 3p21.3 region, frequently affected in common human malignancies. The gene generates two transcripts, 5 and 2 kb-long, full-length Ron (flRon) and short-form Ron (sfRon), respectively. Here, we show for the first time that the variegated Ron expression is associated with variations in the methylation patterns of two distinct CpG islands in Ron proximal promoter. Widespread hypermethylation associates with lack of flRon whereas hypermethylation of the distal island associates with transcription of sfRon, a constitutively active tyrosine-kinase that drives cell proliferation. sfRon inhibition with kinase-dead transgenes decreases cancer cell growth and induces cellular differentiation. sfRon could be a new drug target in cancer types in which it contributes to tumor progression.
Introduction
The receptor tyrosine kinase Ron (MST1R) is expressed in epithelial and hematopoietic cells (reviewed by Camp et al. (2005) ) in the form of a 5 kb (full-length Ron, flRon) and a 2 kb (short-form Ron, sfRon) transcripts. Both the protein products possess the intracellular kinase domain, but only flRon contains the ligandbinding pocket located in the extracellular 'sema' domain (Angeloni et al., 2004) . The differences in the structure have relevant implications for Ron's overall biological functions, as suggested by the striking phenotype differences between the different types of Ron knockout mice in which only exon 1 (Correll et al., 1997) , exons 1-15 (Muraoka et al., 1999) or exon 13-18 (Waltz et al., 2001) were disrupted.
flRon activation, upon binding with its ligand (macrophage stimulating protein, MSP), promotes responses involved in normal development as well as tumorigenesis and metastasis, including cell proliferation, dissociation, motility, matrix invasion and morphological changes known as epithelial-mesenchymal transformation (EMT) (Wang et al., 1996; Danilkovitch-Miagkova et al., 2000 Thiery, 2003) . Notably, ligand activation of Stk, the murine ortholog of Ron, was also reported to induce apoptosis .
Human sfRon mRNA was detected at low levels in several normal adult organs such as colon, skin and lung (Ronsin et al., 1993; Gaudino et al., 1994; Iwama et al., 1996) as well as in lung cancer , erythroleukemia (Bardella et al., 2004) and gastric cancers (Gaudino et al., 1994) . Bardella et al. (2004) showed that epithelial cells transduced with sfRon display an aggressive phenotype and shift to a nonepithelial morphology; they grow faster, become motile and are unable to form aggregates.
sfStk was found expressed in animals susceptible to friend erythroleukemia virus and was absent in resistant animals, in which sfStk-enforced expression restored susceptibility (Persons et al., 1999) .
The observation that different types of cancers (Gaudino et al., 1994; Angeloni et al., 2000; Bardella et al., 2004) show variable amounts of flRon and/or sfRon prompted us to investigate the underlying molecular mechanism of this phenomenon.
Here, we show that Ron's proximal promoter comprises two closely adjacent CpG islands, whose methylation patterns are associated with the expression of flRon/sfRon. Widespread hypermethylation of both the islands associated with the lack of flRon and presence of sfRon, transcribed from an intragenic promoter. Exposing cells with a hypermethylated Ron proximal promoter to 5-aza-2 0 -deoxycytidine restored flRon expression. sfRon protein formed constitutively active, auto-phosphorylated dimers that conferred a growth advantage to the expressing cells. Inactivation of sfRon with dominant-negative kinase-dead variants in lung cancer and erythroleukemia cells inhibited proliferation. In the latter cells, it also induced erythroid differentiation (i.e. hemoglobin production).
We discuss novel mechanisms of expression from Ron promoters and their biological implications in normal and tumor growth.
Results
Ron is expressed in cancer cell lines as the full-length receptor and a short form In a previous analysis of Ron expression in a panel of lung cancer cell lines , we observed that small cell (SCLC) and non-small cell (NSCLC) lung cancer cell lines showed variable levels of expression of the 4.5 kb flRon transcript (undetectable in some cell lines), whereas all SCLC samples showed the 2 kb sfRon transcript.
In this study, we wished to investigate whether the variable flRon expression was related to the methylation status of its promoter. For this purpose, we repeated and extended the Northern analysis to human SCLC, NSCLC and erythroleukemia cell lines (the latter included because of sfRon involvement in murine erythroleukemia, Persons et al., 1999) ; subsequently, we characterized the Ron protein expression and correlated both with the methylation levels of Ron proximal promoter.
sfRon was found in all the cancer cell lines analysed with Northern blotting (Figure 1a and b) . In addition to sfRon, flRon was present in the cell lines H2081, H2198, H2330 (SCLC) and K562 (erythroleukemia) (Figure 1a and b).
Immunostaining experiments with two cell lines in which flRon transcripts were detectable (H2198 and H2330) and two in which they were not (H446 and H661), showed that all the four stained positive with specific anti-Ron antibodies targeting the cytoplasmic, C terminus part of Ron (C20, Santa Cruz, CA, USA, Figure 1d ), but only H2198 and H2330 stained with the N20 antibody that targets the extracellular, N terminus alpha-chain of flRon (N20, Santa Cruz, CA, USA, Figure 1c ). H446 and H661, expressing only sfRon, exhibited a round shape and a looser attachment to the culture plate.
In this way, we identified the cell lines for subsequent promoter methylation studies in which a short, 5 0 -terminal-truncated form of Ron transcript encodes the endogenous sfRon protein.
Distinct methylation patterns of two CpG islands in Ron's proximal promoter associate with the lack of flRon and the presence of sfRon transcription To understand whether the absent or decreased flRon transcript is associated with variable methylation levels, we next studied the methylation status of Ron's proximal promoter (Del Gatto et al., 1995) .
Using CpG islands predictor algorithms available on the world-wide web, we analysed the region of 5856 bp (BAC clone RP11-78O10, GenBank Accession Number AC068701) containing the proximal promoter of Ron plus Ron exon 1 (Del Gatto et al., 1995) . In this sequence, two regions met the criteria of CpG islands, both for CpG content and frequency and for the location with respect to the transcription unit (Figure 2a ). Island 1, about 270 bp long, includes the transcription start site. Island 2, about 320 bp long, is located in the first coding exon.
We performed methylation-specific polymerase chain reaction (PCR) (primer sequences in Table 1 ) on Na bisulfite-treated (Herman et al., 1996) genomic DNA samples of several cancer cell lines and tumor, and matched normal-tissue biopsies (Figure 2b ). CpG island 1 was amplified with a single set of PCR primer pair; CpG island 2, for technical convenience, with two primer sets ('island 2-1' and '2-2').
Initially, we compared four SCLC cell lines with the respective primary tumors of origin for the Ron promoter methylation status, and found it to be similar among the two sets (Table 2) . Then, we extended the study to several other primary tumors (SCLC, NSCLC, cervical squamous cell carcinoma (CSSC) and breast cancer) looking for statistically significant differences of methylation between the tumor and normal samples (Table 3) .
The methylation level of each PCR product was calculated as the percentage of methylated CpG dinucleotides over the total number of CpGs in the specific PCR products (island 1, island 2-1 and 2-2 respectively). In the case of NSCLC, SSC and the breast cancer, we compared normal and tumor DNA from the same patient using a t-test for paired data. In the case of SCLC samples, as no matched normal DNA was available, we compared the methylation level with the normal, adult lung DNA samples from the NSCLC collection, using a t-test for unpaired data with Welch correction.
We found the island 2-2 significantly demethylated in the breast, cervical and NSCLC cancer biopsies as compared to their matched normal tissues (P ¼ 0.015, 0.002 and 0.007, respectively, Table 3 ) and also in SCLC biopsies and cell lines, when compared to the island 2-2 of normal lung samples (P ¼ 0.0002). In addition, we found that island 1 in SCLC, unlike the other cancer samples analysed in this study, was significantly hypermethylated when compared to normal, adult lung tissues (P ¼ 0.0216, Table 3 ). However, methylation of island 1 in SCLC samples did not feature a normal distribution. Rather, most samples showed absent or low methylation (less than 16%), whereas others were well above 60%, with no intermediate classes (Figure 2c ).
In summary, normal adult tissues in which flRon is expressed showed a nearly complete lack of methylation of island 1, whereas island 2 was almost totally methylated. Island 1 was strongly methylated in SCLC biopsies, SCLC and erythroleukemia cell lines, but not in NSCLC, breast and cervical cancer. Island 2 was significantly demethylated in all the cancer samples.
Tumor cell lines in which flRon is expressed also showed lack of methylation in island 1, which was instead hypermethylated coincidentally with the absence of flRon (Table 2) . sfRon transcription was coincidental with methylation of island 2 and seemingly independent from the methylation level of island 1 (Table 2) .
These results suggested that hypermethylation of the proximal promoter might either lead to chromatin modifications capable of activating a downstream, intragenic promoter from which sfRon is transcribed; or activate the intragenic promoter by default, owing to the higher availability of transcription factors common to both promoter regions, as would be expected in promoter competition models (Bix and Locksley, 1998; Saleh et al., 2004) . To substantiate the latter hypothesis, we looked for predicted transcription factor (TF) binding sites common to both the proximal, CpG-type, and the internal, TATA-type, promoters and found several TF that could bind both regions.
Restored expression of flRon in erythroleukemia cell lines after 5-aza-2 0 -deoxycytidine treatment Although the erythroleukemia cell line K562 showed the presence of both flRon and sfRon, TF1 showed sfRon (Figures 1b and 4c ). In TF1, both island 1 and 2 were found heavily methylated (Figure 2b ). flRon transcript (Figure 1b ) and protein ( Figure 1e ; only TF1 is shown) were enhanced after a 5-day exposure to 5 mM 5-aza-2 0 -deoxycytidine, an inhibitor of DNA methyltransferases, confirming that a lack of flRon transcript is associated with promoter hypermethylation, since demethylation is sufficient to reactivate/increase transcription.
The treatment of lung cancer cell lines with 5-aza-2 0 -deoxycytidine yielded similar results (data not shown). Table 2 ). Most samples showed low methylation of island 1 (as in the other cancer types) but some samples were markedly hypermethylated, a feature found also in the erythroleukemia cell line TF1 expressing sfRon only.
Ron promoter variegated methylation and sfRon expression D Angeloni et al
An intragenic promoter located in exon 10 of flRon gene drives the transcription of sfRon After showing that sfRon transcription is associated with abnormal methylation of Ron main promoter, we next looked for the transcription start site of sfRon.
Human vs mouse genomic sequence alignment of the Ron locus identified the region between intron 8 and intron 10 (GenBank Accession number AF164641 and AF164643, respectively) as most likely containing the putative Ron internal promoter. A reporter construct (Materials and methods) was made and transiently transfected into the H446 and H661 cell lines, expressing endogenous sfRon, on the assumption they would possess all factors necessary for activating the putative internal promoter. Indeed upon transfection, the cells started to express GFP (Figure 3b and c) as opposed to non-transfected parental cells (Figure 3a ) or cells transfected with a mock plasmid (Figure 3d ).
In Stk a 3 bp-deletion inside intron 10 inactivates the internal promoter (Persons et al., 1999) . We performed the mutation analysis of the corresponding human genomic region in several SCLC cell lines expressing sfRon and did not find mutations (data not shown).
To identify the 5 0 end of sfRon transcripts, we performed RACE experiments with total and poly A þ RNA isolated from H446 and HEL92 cell lines expressing sfRon only. Three independent experiments with HEL92 mRNA yielded clones with a putative transcription initiation corresponding to nucleotide 2519 (exon 10) of flRon (as in GenBank X70040). Also, alternative splicing forms of exons 11 and 13 were found.
Endogenous sfRon is a constitutively active, autophosphorylating protein that forms disulfide-linked dimers To investigate the biochemical characteristics of sfRon, we first showed with a kinase in vitro assay that endogenous sfRon is an active kinase (Figure 4a) .
The basal activation status of endogenous flRon and sfRon in the cancer cell lines of interest was next studied with Western blotting (Figure 4b-e) . sfRon was found constitutively tyrosine-phosphorylated in the lung cancer cell lines H2330, H446 and H661 (Figure 4b , lower panel), and in all the three erythroleukemia cell lines (Figure 4c ).
To study the biochemical mechanisms underlying sfRon constitutive tyrosine-phosphorylation, we prepared and transfected several mammalian expression constructs carrying human wild-type-sfRon (wt-sfRon) and kinase dead-sfRon (kd-sfRon), with and without V5 tag Based on these results, we hypothesized that sfRon constitutive tyrosine-phosphorylation could be mediated by dimerization of sfRon bringing together two single Ron molecules (similarly to flRon dimerization induced by ligand binding). On this basis, we co-transfected wt-sfRon and kd-sfRon and observed the formation of inactive dimers between the two (Figure 5b) .
In polyacrylamide gel electrophoresis (PAGE) under non-reducing conditions, the sfRon band migrated at approximately 150 kDa ( Figure 5c) ; whereas under reducing conditions migrated below 70 kDa (Figure 5b ), indicating that sfRon forms disulfide-linked dimers, causing sfRon kinase activation and consequent sfRon autophosphorylation.
The finding that co-expression of wt-and kd-sfRon prevents sfRon tyrosine-phosphorylation suggested kdflRon (or native flRon) may also serve as a negative regulator of endogenous sfRon. To test this hypothesis, V5-tagged sfRon (Figure 5a ) and kd-flRon were coexpressed in HEK 293 cells. Using kd-flRon, instead of kd-sfRon, allowed us to distinguish the two Ron molecules based on their molecular weight difference. Our results showed that kd-flRon and wt-sfRon are associated, and this association consequentially inhibits sfRon tyrosine-phosphorylation (Figure 5d and e). These data together with the observation (DanilkovitchMiagkova A, unpublished results) that wt-flRon and wtsfRon when co-expressed in a heterologous system form a protein complex that undergoes rapid degradation, suggested also that sfRon endogenous activity could be affected by endogenous flRon expression.
sfRon confers a growth advantage to expressing cells. Kinase-dead-flRon (kd-flRon) is a dominant-negative regulator of sfRon activity We then investigated whether sfRon conferred a growth advantage on cancer cells (specifically SCLC H446 and erythroleukemia K562 cell lines), and investigated the possibility of interfering with sfRon activity using the mentioned kinase-dead variants. We compared the growth rate of parental or mock-transfected cells with the growth rate of cells, transiently transfected with either the kinase-dead variants of flRon or sfRon. Parental and mock-transfected H446 cells did grow much faster than cells transfected with kinase-dead variants of Ron (Figure 6a ). Kd-flRon exerted a stronger effect compared to kd-sfRon (Figure 6b ). The same was found for the erythroleukemia cell line K562. Five days after plating, the number of cells transfected with kd-flRon was 60% less than in the control culture (Figure 6c) . Moreover, the K562 culture shows that sfRon is an active kinase. The intensity of the band corresponding to phosphorylated MBP (the exogenous substrate) is proportional to the level of Ron kinase activity. Cancer cell lines expressing sfRon (b, c) were starved in serum-free medium. In these conditions, sfRon was found constitutively tyrosine-phosphorylated in the lung cancer cell lines H446 and H661 (d, lower panel), and in all three erythroleukemia cell lines (e). C20 and anti-PY antibodies recognize their target with dissimilar efficiency, which explains the diverse intensity of sfRon bands in the two types of WB. The human U937 histiocytic leukemia cell line was used as a negative control. Human wt sfRon and kd variants were generated based on the RACE experiment results. In WB (C20 antibody) after PAGE in reducing conditions, sfRon migrates below 70 kDa (b, upper panel), whereas in non-reducing conditions sfRon migrates as approximately 150 kDa (c, upper panel), suggesting that sfRon can form disulfide-linked dimers. Co-expression of transfected wt-sfRon and kd-sfRon resulted in complete inhibition of sfRon tyrosine-phosphorylation, shown by lack of signal in WB with anti-PY antibody, both after PAGE in reducing (b, lower panel) and in non-reducing condition (c, lower panel), suggesting that sfRon disulfide-linked dimers cause sfRon kinase activation and consequent autophosphorylation (and lack thereof in case of kinase-dead variants). To understand whether kd-flRon can also serve as a negative regulator of endogenous sfRon, kd-flRon and sfRon-V5 were co-expressed in HEK 293. Results show that kd-flRon and wt-sfRon were associated, and this association resulted in inhibition of sfRon tyrosine-phosphorylation (b, e). IP: C20 (b, c), N20 (d) and anti-V5 (e) antibody. WB: C20 and anti-PY antibody.
Ron promoter variegated methylation and sfRon expression D Angeloni et al expressing kd-flRon contained 40-60% hemoglobinpositive cells, vs 10% hemoglobin-positive cells in the control culture (Figure 6d ). The erythroid differentiation was also visible by the red color of transfected cells (Figure 6f ). Transfected kd-flRon also caused a reduction of sfRon amount and tyrosine-phosphorylation (Figure 6e ).
Discussion
Others and we reported the existence of sfRon, which although quite low in expression, was found in normal tissues and cancer cell lines (Ronsin et al., 1993; Angeloni et al., 2000; Bardella et al., 2004) . Both forms of Ron were implicated in cell growth and motility, although with possible functional differences as suggested by the positive selection of both forms across evolution (murine Stk is also transcribed as a full-length and short-form, Persons et al., 1999) .
To investigate the mechanism underlying the twofold Ron expression, first we identified cancer cell lines in which either or both forms were present (Figure 1 ). In these cell lines, and in a larger collection of tumor biopsies and matched normal tissues, we studied the methylation status of two CpG islands located in Ron proximal promoter (Figure 2) .
We found essentially two patterns of methylation. In normal breast, lung and cervical tissue, island 1 was very scarcely methylated, whereas island 2 was completely methylated. In contrast, island 1 was found extensively hypermethylated in several SCLC biopsies and cell lines and erythroleukemia cell lines. Island 2 was found In the cancer cell lines examined, the variegated patterns of methylation correlated with the expression of flRon: low/absent methylation of island 1 and methylation of island 2 associated with the presence of flRon, whereas hypermethylation of island 1 and strong methylation of island 2 associated with the absence of flRon and the presence of sfRon (Table 2) .
We suggest at least two possibilities to explain these observations: hypermethylation of the proximal promoter (1) might lead to chromatin modifications enabling the activation of a downstream, intragenic promoter from which sfRon is transcribed; or (2) it could activate the intragenic promoter by default, owing to the higher availability of transcription factors (TF) common to both promoter regions, as expected in promotercompetition models (Bix and Locksley, 1998; Saleh et al., 2004) . The presence of predicted TF-binding sites common to both the proximal (CpG-type) and the internal (TATA-type) promoters is therefore indicative and, if verified experimentally, would support such model.
With RACE studies, sfRon was found to originate from an intragenic promoter located in exon 10 (Figure 3) .
The expression of flRon was restored in cancer cells treated with 5-aza-2 0 -deoxycytidine, which confirmed that lack of flRon transcript was associated with promoter hypermethylation as demethylation was sufficient to reactivate flRon transcription (Figure 1) .
Demethylation of island 2, found in tumor biopsies, may perhaps explain flRon overexpression reported in several types of cancer (Camp et al., 2005) , among which are NSCLC and breast cancer.
Interestingly, alternative splicing forms of exons 11 and 13 were found in diverse RACE clones. They may account for multiple Ron bands visible below 70 kDa in Western blotting and may be indicative of the diverse mechanisms regulating Ron signaling specificity (Ghigna et al., 2005) . For example, the amino acids 1002-DYR-1004 in exon 13, conserved in Met and essential for the interaction with protein tyrosinephosphatase-S (PTP-S, Villa-Moruzzi et al., 1998), are evolutionary conserved in several Ron orthologs, except Stk, and are likely important for the downregulation exerted by PTP-S on the activated receptor. Previously, we noticed that Stk lacks what corresponds to human exon 13. Recently it was shown (Wei et al., 2005) that this difference represents part of the diversification between human Ron and murine Stk signaling activity.
Endogenous sfRon is a constitutively active kinase forming disulfide-linked, autophosphorylating dimers (Figures 4 and 5 ) whose presence conferred a distinctive growth advantage to expressing cancer cells, as suggested by the decreased cell-growth rate caused by transfection with either of kd variants ( Figure 5 ). Cotransfection of wt and kd-sfRon resulted in the complete inhibition of sfRon tyrosine-phosphorylation ( Figure 5 ). kd-flRon also exerted a dominant-negative effect on sfRon, suggesting that wt-flRon and sfRon may interact ( Figure 5 ). Most likely, the inhibiting effect is mediated through the formation of a hetero-complex promptly degraded by the cell. kd-flRon's effect was stronger than kd-sfRon's (Figure 6 ), possibly because the heterodimer kd-flRon/sfRon is degraded faster, or because kd-flRon interacts also with endogenous flRon when present.
The observation that sfRon, with its intrinsic oncogenic potential, is also present in normal tissues (Ronsin et al., 1993; Gaudino et al., 1994; Iwama et al., 1996) led us to speculate; but further studies are required, that sfRon might be preferentially expressed in rapidly growing cells during normal development or adult tissue renewal, whereas the ratio of both forms would control tissue homeostasis. In the tumor cells, this ratio could be tilted toward driving proliferation, invasion and rapid tumor growth. In fact, the expression of kd dominantnegative constructs in cancer cells causes exit from cell cycle and differentiation (as evidenced by the hemoglobin production in erythroleukemia cells). Therefore, it is possible that variegated patterns of methylation of CpG islands controlling the expression of the two Ron forms may in fact represent a dynamic tool for modulating the ratio of the two Ron forms.
Lastly, a possibility may exist that sfRon transcription is independent of flRon transcription. To rule this out, we would need to study Ron promoter methylation in cells in which sfRon is absent (not found in this study).
In conclusion, our results suggest a previously unknown molecular mechanism of subversion in cancer of the normal control of Ron tyrosine-kinase expression. The control of Ron transcription by promoter methylation is in agreement with the epigenetic views of promoter silencing in cancer. However, the discovery that two promoters, coexisting in the same gene and controlling the long and short form of the protein with differing and common functions, are regulated by the variegated DNA methylation patterns of the proximal promoter CpG islands is new, and reported for the first time here. The molecular mechanisms and governing signals involved remain undiscovered. Carninci et al. (2006) reported recently that, in a genome-wide scale, multiple promoters, belonging to different classes, could be located within single-gene loci, also including their exons. In this combinatorial vision of the transcriptome, Ron's complex transcriptional regulation should not be considered an isolated case.
Finally, we would like to point out that kd-Ron dominant-negative constructs, capable of inducing differentiation by inhibiting sfRon activity, could represent novel therapeutic tools for sfRon-expressing cancers, specifically for erythroleukemia, to complement the pharmacological approach with aza-cytidine derivatives. Although successfully used in clinic (especially in hematopoietic malignancies, Momparler, 2005) , it is a non-specific approach susceptible to activating genes, along with other genes for growth control, with unknown effect.
Materials and methods
Human DNA Tumor cell lines were established from lung cancer patients according to techniques described previously (Phelps et al., 1996) . Tumor and normal tissue were obtained from patients at surgical resection or post-mortem examination (Johnson et al., 1988) . Signed, informed consent was obtained from all the participants in the study, according to the NCI institutional review board-approved protocol.
Cell lines and culture conditions All cell lines were from ATCC (Manassas, VA, USA) and were cultured according to ATCC recommendations.
Antibodies
Rabbit C20 (against the C-terminal part of human Ron) and N20 anti-Ron antibodies (against the N-terminal part of human Ron): Santa Cruz, CA, USA. Anti-phosphotyrosine antibody, PY, (clone 4G10): UBI (Lake Placid, NY, USA). Anti-V5 antibody: Invitrogen (Carlsbad, CA, USA). Mouse monoclonal ID2 antibody (against the N-terminal domain of human Ron): a gift from Dr F Montero-Julian (Immunotech, France).
Vectors and constructs
For transfection studies, flRon and sfRon were cloned into pcDNA3.1-V5-His (Invitrogen Carlsbad CA, USA) and pFLAG-CMV2 (Sigma, St Louis, MO, USA).
Cell lysis, immunoprecipitation and Western blotting
Cells were starved in serum-free medium for 4 h. After starvation cells were lysed in lysis buffer (50 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES), pH 7.4, 150 mM NaCl, 1% Triton X-100, 10% glycerol, 1 mM ethylenediaminetetra aceticacid (EDTA), 1 mM sodium orthovandate, 10 mM sodium pyrophosphate, 100 mM NaF, 10 mg of leupeptine/ml, 10 U of aprotinin/ml and 1 mM PMSF). Cell lysates were clarified and then immunoprecipitated or used directly for sodium dodecyl sulfate (SDS)-PAGE and Western blotting. 
Computational analysis

Erythroid differentiation assay
Hemoglobin-positive cells stained with benzidine were used to evaluate erythroid differentiation. The percentage of benzidine-positive cells was determined by counting at least 500 cells by the wet benzidine method as described (Talley et al., 1997) .
Immunohistochemistry Adherent-growing cells were seeded 12 h before the experiment into eight-well chamber slides (Lab-Tek II System, Nalge Nunc Int., Naperville, IL, USA) in the appropriate medium, at 371C in CO 2 incubator, washed (1 Â phosphate-buffered saline (PBS)) and fixed with methanol/acetone 1:1 (2 min at room temperature (RT)), washed again, permeabilized (0.5% Triton X-100, 50 mM NaCl, 3 mM MgCl 2 , 20mM HEPES, 10% sucrose) for 10 min at RT, and blocked (20 mg/ml gelatin, 20% fetal bovine serum) for 1 h at RT. Incubation with primary antibody (N20, C20 or A15, Santa Cruz, CA, USA) was carried out for 3 h at RT in 0.1% gelatin, 0.4% fetal bovine serum. After several washes (1 Â PBS), slides were incubated with biotinylated goat anti-rabbit secondary antibody (ABC-AP Kit, Vector Laboratories, Burlingame, CA, USA), and then the alkaline phosphatase substrate (Vector Red, Vector Laboratories, Burlingame, CA, USA) was added. After 20 min at RT, the slides were rinsed, mounted in Permont medium (Fisher Scientific, Itasca, IL, USA) and coverslipped for microphotography.
Kinase in vitro assay
Ron was immunoprecipitated from cell lysates of erythroleukemia cell lines with C20 antibody. Immunoprecipitates were washed twice in HNTG buffer (50 mM HEPES, pH 7.4, 150 mM NaCl, 0.1% Triton X-100 and 10% glycerol) and twice in kinase buffer (20 mM HEPES, pH 7.4, 150 mM NaCl, 10 mM MgCl 2 , 10 mM MnCl 2 and 10% glycerol). To initiate kinase reactions, 15 mC i [g 32 -P]-ATP (3000 C i /mmol, 10 mC i /ml) and the exogenous substrate, myelin basic protein (MBP, at a concentration of 0.5 mg/reaction tube, Gaudino et al., 1994) were added to the kinase reaction mixture. Immunoprecipitates were incubated 30 min, at RT in 15 ml total volume. Reactions were stopped with 5 ml of 4Â sample buffer. Phosphorylated MBP was visualized by autoradiography after SDS-PAGE.
Methylation analysis of Ron promoter
Genomic DNA samples were treated with Na bisulfite as described (Herman et al., 1996) . Methylation specific PCR was carried out with primers listed in Table 1 , and conditions as follow: first PCR: 3 min at 941C; (30 s at 941C, 1 min at 541C, 1 min at 721C) Â 35; 7 min at 721C; nested PCR: 3 min at 941C; (30 s at 941C, 1 min at 581C, 1 min at 721C) Â 35; 7 min at 721C. PCR products were directly sequenced or cloned into pCR2.1 (TOPO TA Cloning Kit, Invitrogen).
Northern blotting mRNA was extracted with Fast Track2.0. Kit (Invitrogen) and filters were prepared and hybridized according to Sambrook et al. (2001) . The radioactive DNA probe (plasmid-free, flRon cDNA) was prepared by random priming (Rediprime II, Amersham, Arlington Heights, IL, USA). Hybridization was performed in ExpressHyb hybridization solution according to the manufacturer's instructions (Clontech Laboratories, Palo Alto, CA, USA). Filters were exposed to autoradiography film (X-OMAT AR, Kodak, Rochester, NY, USA) at À801C with intensifier screens.
Rapid amplification of cDNA ends experiment Total RNA extraction: RNA STAT-60 (Tel-Test; Friendswood, TX, USA), Poly A þ RNA extraction: Fast Track 2.0 Kit (Invitrogen). RACE was performed with SMART RACE Kit (Clontech, Palo Alto, CA, USA), using for retrotranscription 1 mg of total RNA and 1.2 mg of poly-A þ .
Several consecutively nested reverse primers were designed, with Tm>701C, according to the RACE Kit manufacturer's instructions. Primers: ABL Applied Biosystems (Frederick, MD, USA), sequence in Table 1 . RACE cycling: 941C, 4 min; (941C, 30 s; 701C, 30 s; 721C, 2 min) Â 30; 721C, 7 min. Nested-RACE cycling: 941C, 4 min; (941C, 30 s; 68/641C, 30 s; 721C, 2 min) Â 30; 721C, 7 min. All PCR products were cloned and sequenced.
Ron internal promoter reporter study The NCI-H446 and H661 cell lines were transfected with a construct containing a fragment of genomic DNA located between intron 8 and intron 10 of the human Ron gene (containing the putative Ron internal promoter), PCRamplified from a healthy individual and cloned upstream the promoter-free green fluorescent protein (GFP)-coding sequence of pGlow-TOPO, following the manufacturer's instructions (pGlow-TOPO TA Cloning Kit, Invitrogen). PCR primers: ABL Applied Biosystems (Frederick, MD, USA), sequence in Table 1 . PCR cycling conditions: 4 min at 941C; (30 s at 921C, 30 s at 621C, 1 min at 721C) Â 35; 7 min at 721C. The mock construct was a random, same-length genomic DNA fragment cloned into the same vector.
Sequencing
Sequencing reactions were carried out either manually (T7 Sequenase Kit, Amersham, Arlington Heights, IL, USA) or automatically (ABI 373 Stretch Automated DNA Sequencer, Applied Biosystems, Foster City, CA, USA).
Transfection
All transfections were carried out with Lipofectamine 2000 carrier (Invitrogen) according to the manufacturer's instruction.
Statistical analysis
Comparisons between mean values were performed with twotailed paired-sample t-test (for breast, cervix and NSCLC) and two-tailed unpaired-sample t-test with Welch correction (SCLC). A P-value less than 0.05 was considered statistically significant. Mean values and s.d. are reported.
